NeuroGenesis Bio Receives FDA Clearance for NG01 Expanded Access
The FDA cleared NeuroGenesis Bio to proceed with an expanded access program for NG01 in progressive multiple sclerosis.
The FDA cleared NeuroGenesis Bio to proceed with an expanded access program for NG01 in progressive multiple sclerosis.